ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
22 hedge funds and large institutions have $16.1M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
6% more capital invested
Capital invested by funds: $15.1M → $16.1M (+$962K)
5% more funds holding
Funds holding: 21 → 22 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.96% less ownership
Funds ownership: 36.78% → 33.82% (-3%)
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
BCWM LLC
Overland Park,
Kansas
|
+$240K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$193K |
| 3 |
LWPC
Legacy Wealth Partners (California)
Calabasas,
California
|
+$185K |
| 4 |
PWM
Perigon Wealth Management
San Francisco,
California
|
+$30K |
| 5 |
AP
Atwood & Palmer
Kansas City,
Missouri
|
+$19.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$892K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$465K |
| 3 |
Jane Street
New York
|
-$347K |
| 4 |
LPL Financial
San Diego,
California
|
-$114K |
| 5 |
Citigroup
New York
|
-$30K |
CNCR Hedge Fund Activity: Q4 2020 in Review
22 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q4 2020, worth a combined $16.1M — up 6.4% from $15.1M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CNCR positions and 3 closed out — a net gain of 2 holders — while 4 added to existing stakes and 11 trimmed.
The largest buyer was BCWM LLC, adding an estimated $240K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $892K sold.
- 22 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q4 2020, up from 21 in Q3 2020.
- Funds reported $16.1M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q4 2020, up 6.4% quarter-over-quarter.
- 5 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q4 2020 and 3 closed out, a net change of +2 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q4 2020 was BCWM LLC, an estimated $240K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q4 2020 was Susquehanna International Group, an estimated $892K sold.
Based on aggregated 13F filings for Q4 2020.